Natera stock forecast 2025 investment desks cite that the "Natera

Investment desks cite that the "Natera stock forecast 2025" could outperform biotech peers, leveraging its unique data analytics in cancer monitoring to increase recurring revenues. Despite the variation in price targets, the company remains an attractive investment due to its strong revenue growth, leadership in genetic testing, and expanding market presence. The company’s ability to outperform expectations while steadily reducing losses suggests it is on a solid trajectory toward profitability. With continued advancements in genetic testing and growing demand for precision medicine, Natera, Inc. (NASDAQ:NTRA) is well-positioned to capitalize on long-term industry trends, making it a compelling stock for investors seeking exposure to the healthcare innovation sector. CEO Steve Chapman attributed the quarter’s performance to “record Signatera growth” and ongoing strength in the women’s health and organ health product lines. Forward EBITDA projections suggest the "Natera stock forecast 2025" could reach $220M, supporting valuation expansion if biotech sentiment remains resilient.